Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 7

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 7
---
 marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this proxy statement appear without the ®and ™ symbols, but those references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent under applicable law, the Company’s rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames. iv CERO THERAPEUTICS HOLDINGS, INC. 201 Haskins Way, Suite 230
South San Francisco, CA 94080 PROXY STATEMENT 2025 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON , 2025 GENERAL INFORMATION Why did I receive this proxy statement? This proxy statement and the enclosed proxy card are being sent to you in connection with the solicitation of proxies by the Company for use at the 2025 Annual Meeting of Stockholders (the “Annual Meeting”), or at any adjournments or postponements thereof. This proxy statement summarizes the information that you need to make an informed decision on the proposals to be considered at the Annual Meeting. The Annual Meeting will be held virtually via live interactive webcast on the internet on, 2025 atPacific Time. If you held shares of the Company’s common stock, on March31, 2025 (the “Record Date”), you are invited to attend the Annual Meeting at https://www.cstproxy.com/cero/2025and vote on the proposals described below under the heading “What am I voting on?” When is the record date for the Annual Meeting? The record date for determination of stockholders entitled to vote at the Annual Meeting is the close of business on March31, 2025. What am I voting on? There are six proposals scheduled to be voted on at the Annual Meeting: • Proposal No. 1:The approval of an amendment to our Second Amended and Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”) to combine outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) into a lesser number of outstanding shares (the “Reverse Stock Split”), by a ratio of not less than one -for- and not more than one -for- , with the exact ratio to be set within this range by our Board in its sole discretion (the “Reverse Stock Split Proposal” or “Proposal No. 1”). • Proposal No. 2:The approval, subject to certain